Aquestive Therapeutics, Inc. AQST Interest Expense, Sale of Future Revenues
Interest Expense, Sale of Future Revenues at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:InterestExpenseSaleOfFutureRevenues.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s interest expense, sale of future revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s interest expense, sale of future revenues?
- Aquestive Therapeutics, Inc. (AQST) reported interest expense, sale of future revenues of $60K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s interest expense, sale of future revenues changed year-over-year?
- Aquestive Therapeutics, Inc.'s interest expense, sale of future revenues increased by 1.7% year-over-year, from $59K to $60K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s interest expense, sale of future revenues?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s interest expense, sale of future revenues has grown at a -62.6% compound annual growth rate (CAGR), from $12.41M to $243K.
- What does interest expense, sale of future revenues mean?
- This metric represents the financing costs associated with monetization agreements where the company receives upfront capital in exchange for a portion of future revenue streams. It serves as a measure of the cost of alternative financing structures used to fund operations or development. Investors track this to understand the long-term impact of debt-like obligations tied to future product sales.